High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells

S Oppermann, J Ylanko, Y Shi… - Blood, The Journal …, 2016 - ashpublications.org
S Oppermann, J Ylanko, Y Shi, S Hariharan, CC Oakes, PM Brauer, JC Zúñiga-Pflücker
Blood, The Journal of the American Society of Hematology, 2016ashpublications.org
Novel agents such as the Bcl-2 inhibitor venetoclax (ABT-199) are changing treatment
paradigms for chronic lymphocytic leukemia (CLL) but important problems remain. Although
some patients exhibit deep and durable responses to venetoclax as a single agent, other
patients harbor subpopulations of resistant leukemia cells that mediate disease recurrence.
One hypothesis for the origin of resistance to venetoclax is by kinase-mediated survival
signals encountered in proliferation centers that may be unique for individual patients. An in …
Abstract
Novel agents such as the Bcl-2 inhibitor venetoclax (ABT-199) are changing treatment paradigms for chronic lymphocytic leukemia (CLL) but important problems remain. Although some patients exhibit deep and durable responses to venetoclax as a single agent, other patients harbor subpopulations of resistant leukemia cells that mediate disease recurrence. One hypothesis for the origin of resistance to venetoclax is by kinase-mediated survival signals encountered in proliferation centers that may be unique for individual patients. An in vitro microenvironment model was developed with primary CLL cells that could be incorporated into an automated high-content microscopy-based screen of kinase inhibitors (KIs) to identify agents that may improve venetoclax therapy in a personalized manner. Marked interpatient variability was noted for which KIs were effective; nevertheless, sunitinib was identified as the most common clinically available KI effective in overcoming venetoclax resistance. Examination of the underlying mechanisms indicated that venetoclax resistance may be induced by microenvironmental signals that upregulate antiapoptotic Bcl-xl, Mcl-1, and A1, which can be counteracted more efficiently by sunitinib than by ibrutinib or idelalisib. Although patient-specific drug responses are common, for many patients, combination therapy with sunitinib may significantly improve the therapeutic efficacy of venetoclax.
ashpublications.org